MedWatch

GN Hearing CEO: R&D organization is back on top form

After a particularly eventful 2021, GN Hearing CEO Gitte Aabo says the hearing aid manufacturer will have overcome last year’s product delays in the second quarter.

Gitte Aabo, CEO of GN Hearing | Photo: GN Hearing / PR

Last year, hearing aid manufacturer GN Hearing experienced a number of product delays, and also parted with its former head of research and development. Now, GN is back on track and ready to win market shares, says the company’s CEO Gitte Aabo, Danish business daily Børsen reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs